These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21169473)

  • 1. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer.
    Garassino MC; Marabese M; Rusconi P; Rulli E; Martelli O; Farina G; Scanni A; Broggini M
    Ann Oncol; 2011 Jan; 22(1):235-237. PubMed ID: 21169473
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
    Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
    Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K-ras mutations in lung cancer: the "mysterious mutation".
    Hirsch FR
    Clin Lung Cancer; 2006 Jul; 8(1):11-2. PubMed ID: 16870039
    [No Abstract]   [Full Text] [Related]  

  • 4. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
    Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
    Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.
    Linardou H; Dahabreh IJ; Kanaloupiti D; Siannis F; Bafaloukos D; Kosmidis P; Papadimitriou CA; Murray S
    Lancet Oncol; 2008 Oct; 9(10):962-72. PubMed ID: 18804418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
    Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
    Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
    Rodenhuis S; Boerrigter L; Top B; Slebos RJ; Mooi WJ; van't Veer L; van Zandwijk N
    J Clin Oncol; 1997 Jan; 15(1):285-91. PubMed ID: 8996154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma.
    Strazisar M; Mlakar V; Glavac D
    Lung Cancer; 2009 Jun; 64(3):257-62. PubMed ID: 19008013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
    Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
    Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer].
    Cvetković G; Plavec G; Tomić I; Ilić V; Magić Z; Tatomirović Z; Novković D; Milić R; Karlicić V
    Vojnosanit Pregl; 2009 Feb; 66(2):149-55. PubMed ID: 19281127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.
    Mitsudomi T; Viallet J; Mulshine JL; Linnoila RI; Minna JD; Gazdar AF
    Oncogene; 1991 Aug; 6(8):1353-62. PubMed ID: 1679529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients.
    Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
    Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
    Graziano SL; Gamble GP; Newman NB; Abbott LZ; Rooney M; Mookherjee S; Lamb ML; Kohman LJ; Poiesz BJ
    J Clin Oncol; 1999 Feb; 17(2):668-75. PubMed ID: 10080613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
    Furugaki K; Iwai T; Shirane M; Kondoh K; Moriya Y; Mori K
    Oncol Rep; 2010 Nov; 24(5):1141-6. PubMed ID: 20878103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.
    Jones S
    Pharmacogenomics; 2014 May; 15(7):903-4. PubMed ID: 25090664
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
    Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A
    Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point mutation of K-ras gene in cisplatin-induced lung tumours in A/J mice.
    Hisamoto A; Kondo E; Kiura K; Okada T; Hosokawa S; Mimoto J; Takigawa N; Tabata M; Tanimoto M
    Lung Cancer; 2007 Oct; 58(1):15-20. PubMed ID: 17604873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Across the universe of K-RAS mutations in non-small-cell-lung cancer.
    Piva S; Ganzinelli M; Garassino MC; Caiola E; Farina G; Broggini M; Marabese M
    Curr Pharm Des; 2014; 20(24):3933-43. PubMed ID: 24138715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.
    Nakajima T; Yasufuku K; Nakagawara A; Kimura H; Yoshino I
    Chest; 2011 Nov; 140(5):1319-1324. PubMed ID: 21527506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
    Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
    Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.